Pharm-Olam's response to COVID-19 from CEO Rob Davie, PhD. Read Here
Check out our latest white paper! We partnered with Informa Pharma Intelligence to bring you the latest information on COVID-19 and its effect on the clinical landscape.
In rare disease, every patient matters and it is important for CRO and sponsor medical staff to effectively monitor and...
The United Kingdom officially withdrew from the European Union (EU) on Jan 31, 2020. They have until Dec 31, 2020 to complete...
Pharm-Olam, as a global CRO, has over 20 years' experience conducting clinical trials in Central and Eastern Europe (CEE). In...
Pharm-Olam is an allergy focused CRO and have worked on over 35 allergy clinical trials. In this article, we explore the area...
Effective Data management plays a critical role in the conduct of clinical trials. Clinical research requires quality data...
Pharm-Olam is a clinical research organization (CRO) that has vast experience in rare diseases. To date, we have completed...
Conducting Phase I studies is always complex. At this stage in clinical research, you are examining the tolerability of the...
In a world with COVID-19, remote monitoring is now essential to effectively monitor studies. Sponsors and CROs are either...
Tags: Pharm-Olam Insights, COVID-19
Subscribe to our blog and we'll give you our GDPR Controller & Processor Checklist.
